BRIEF-Durect completes enrollment in persist, phase 3 trial for Posimir

* Durect completes enrollment in Persist, phase 3 trial for Posimir
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.